StemRIM (TSE:4599) Other Stockholders Equity: 円1,489.38 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4599 StemRIM Inc TSE:4599
31 GF Score
Price 円294.00
! 2 Warning Signs
View Full Analysis

What is StemRIM Other Stockholders Equity?

StemRIM TSE:4599 -1.01% 31 Other Stockholders Equity is 円1,489.38 Mil as of Jan. 2026. GuruFocus rates TSE:4599 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

StemRIM's Other Stockholders Equity for the quarter that ended in Jan. 2026 was 円1,489.38 Mil.

StemRIM's quarterly Other Stockholders Equity increased from Jul. 2025 (円1,452.73 Mil) to Oct. 2025 (円1,484.12 Mil) and increased from Oct. 2025 (円1,484.12 Mil) to Jan. 2026 (円1,489.38 Mil).

StemRIM's annual Other Stockholders Equity increased from Jul. 2023 (円1,174.79 Mil) to Jul. 2024 (円1,314.89 Mil) and increased from Jul. 2024 (円1,314.89 Mil) to Jul. 2025 (円1,452.73 Mil).

StemRIM Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for StemRIM's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemRIM Other Stockholders Equity Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 398.49 891.48 1,174.79 1,314.89 1,452.73

StemRIM Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,429.93 1,452.73 1,484.12 1,489.38 1,521.34
TSE:4599
31GF Score
StemRIM Inc TSE:4599
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemRIM Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円1,489.38 Mil mean?
StemRIM (TSE:4599) has a Other Stockholders Equity of 円1,489.38 Mil as of Jan. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on StemRIM and its competitors.
Is StemRIM's Other Stockholders Equity too high?
StemRIM's current Other Stockholders Equity is 円1,489.38 Mil. Overall, StemRIM has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does StemRIM's Other Stockholders Equity compare to VRTX and REGN?
StemRIM's Other Stockholders Equity of 円1,489.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on StemRIM and its competitors. StemRIM's current Other Stockholders Equity is 円1,489.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemRIM stock overvalued right now?
StemRIM (TSE:4599) has a current Other Stockholders Equity of 円1,489.38 Mil. The current Other Stockholders Equity is 円1,489.38 Mil. StemRIM's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For StemRIM (TSE:4599), the current Other Stockholders Equity is 円1,489.38 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemRIM Business Description

Address 7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.
31GF Score

Get the complete analysis for TSE:4599

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円294.00
Price